Over the past decade, innate lymphoid cells (ILCs) have been identified as a subpopulation of innate immune cells. These cells exist mostly in intestinal mucosal tissue and express no lymphoid differentiation lineage negative (Lin − ) markers and antigen-specific receptors that make them distinct from T cells or B cells (1). They were originally classified as ILC1, ILC2, and ILC3 based on their phenotypic features and functions (2). ILC1 cells secrete interferon-γ (IFN-γ) after interleukin-12 (IL-12), IL-15, and IL-18 stimulation and express the transcription factor T-bet (3). ILC2 cells mainly produce the type 2 T helper cells like cytokines IL-5, IL-9, and IL-13 in response to the stimulation of IL-25 and IL-33 in the presence of the transcriptional factor GATA3 (4). ILC3 cells largely generate IFN-γ, IL-17, and IL-22 under the stimulation of IL-1 and IL-23 in the presence of the transcription factors RORγt and aryl hydrocarbon receptor (AhR) (5). Hence, the ILCs participate in the formation of mucosal immunity, development of lymphoid cells, rehabilitation of tissue injury, and the protection of epithelial barriers.
However, in a recent study published in Cell (6), Lin − CD45 + CD127 + IL-10 + cells were, for the first time, recognized to represent a novel subset of the IL-10-producing ILCs in mice, called regulatory ILCs (ILCreg). These are mostly present in the gut tissue and differentiate and mature in response to pathogen stimulation. In comparison with other ILCs or regulatory T cells (Treg), the ILCreg possess an exclusive gene identity. They express neither CD4 nor FoxP3, the signature marker of Treg cells (6) , but are morphologically similar to lymphoid cells with a high nuclear to cytoplasmic ratio. In addition, the authors reported that the ILCreg expressed various phenotypic ILC markers, including CD25 (IL-2Rα), Sca-1, and CD90 (Thy1), but not ILC1 (NK1.1 and NKp46), ILC2 (ST2 and KLRG1), or ILC3 markers (NKp46, CD4, and RORγt) in inflamed intestinal tissue. The ILCreg inhibited the activation of ILC1 and ILC3 via secretion of IL-10 but did not affect ILC2 with undetectable Il10rb expression, showing that it is a novel ILC subpopulation discriminated from other ILC subsets.
Interestingly, Seehus et al. (7) described a distinct subpopulation of IL-10-producing lung ILC2 cells, termed ILC210, that can suppress pathogenic inflammatory immune responses. Unlike most lung ILC2 with the Thy1.1-negative phenotype, the ILC210 are Thy1.1-positive, generate IL10 to exert modulating roles under the stimulation of IL-33 and downregulate proinflammatory genes, such as Tnf, Lta, Il2, and Ccl1. The ILC210 produce higher levels of transcription factors Id3, Foxf1, Atf3, and Klf2 than ILC2. IL-33 and IL7 instruct ILC2 to produce IL-13, but have no effect on the ILC210 Regulatory Innate Lymphoid Cells Frontiers in Immunology | www.frontiersin.org
July 2018 | Volume 9 | Article 1522 in vitro. Analogous to the ILCreg, the ILC210 have no expression of Foxp3, and IL-2 signaling promotes IL-10 production from ILC210. However, they also express the anti-inflammatory gene Retnla, suggesting that the ILC210 may possess anti-inflammatory properties. Interestingly, the ILC210 exhibit memory-like properties in vivo. The ILC210 are in a resting status after in vivo stimulation is discontinued, but are swiftly reactivated and expanded once again when re-stimulated by a minimal dose of IL-33, similar to memory T cells (7) . In addition, a third regulatory subset, CD56 + CD3 − ILCs were recently described to have regulatory functions in human and mice. They simultaneously express NK cell-and ILC-associated molecules, including CD56, FIGure 1 | Development and potential functions of regulatory innate lymphoid cells (ILCreg). The ILCreg originate from CHILP not ILCPs and depend on the transcriptional factors Id3 and SOX4. The ILCreg can inhibit the activation of ILC1 and ILC3 to relieve innate intestinal inflammation via IL-10 secretion, and promote self-expansion by secreting TGF-β during inflammation. Abbreviations: CLP, common lymphoid progenitor; CHILP, common helper-like innate lymphoid precursor; EILP, early innate lymphoid precursor; PLZF, promyelocytic leukemia zinc finger; NKP, NK cell progenitor; AhR, aryl hydrocarbon receptor; NFIL3, nuclear factor interleukin 3; GATA3, GATA-binding protein 3; ID2, inhibitor of DNA binding 2; ILCP, ILC precursor; ROR, retinoic acid receptor-related orphan receptor; IFN-γ, interferon-γ; ID3, inhibitor of DNA binding 3; SOX4, sex-determining region Y-box 4; TCF1, T cell factor-1; T-bet, T-box expressed in T cells; TGF-β, transforming growth factor-β.
